Akshay Vaishnaw
Director
Health care
Visterra
Denmark
Biography
Akshay Vaishnaw is Executive Vice President and Chief Medical Officer of Alnylam Pharmaceuticals, Inc., which he joined in 2006. Under his leadership at Alnylam, the company is developing a novel class of medicines, RNAi therapeutics, from which seven distinct programs have entered clinical trials. Previously, Dr. Vaishnaw was Senior Director, Translational Medicine at Biogen, Inc. (now Biogen Idec Inc.), where he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Dr. Vaishnaw received his MD from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his PhD from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K.
Research Interest
health care
